Who and what is AirPROM?

AirPROM stands for ‘Airway Disease Predicting Outcomes through Patient Specific Computational Modelling’. The AirPROM consortium involves partners from academia, the Biopharma industry , patient/care organisations and small-to-medium enterprises. By encompassing representatives of all stakeholders we aim to integrate and enhance the capacities of all partners to deliver the best possible outcome for people with asthma and chronic obstructive pulmonary disease (COPD).

At a practical level, AirPROM  brings together existing clinical consortia (EvA FP7, U-BIOPRED IMI and BTS Severe Asthma), with expertise in physiology, radiology, image analysis, bioengineering, data harmonization,  security and ethics, computational modeling and systems biology. The project is funded by the EU.

This broad multi discipline approach will enable the consortium to develop an integrated multi-scale airways model. This model will build on the legacy of existing models and will be comprised of an integrated ‘micro-scale’ and ‘macro-scale’ airway model informed and validated using established techniques and utilising Europe’s largest airway disease cohort.